{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T03:44:11Z","timestamp":1790999051413,"version":"4.1.0"},"reference-count":67,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,23]],"date-time":"2025-01-23T00:00:00Z","timestamp":1737590400000},"content-version":"am","delay-in-days":357,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jvir.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Vascular and Interventional Radiology"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1016\/j.jvir.2023.10.019","type":"journal-article","created":{"date-parts":[[2024,1,23]],"date-time":"2024-01-23T03:01:07Z","timestamp":1705978867000},"page":"178-184","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Immune Effects of Intra-Arterial Liver-Directed Therapies"],"prefix":"10.1016","volume":"35","author":[{"given":"Anita","family":"Karimi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3127-9222","authenticated-orcid":false,"given":"Hooman","family":"Yarmohammadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1876-727X","authenticated-orcid":false,"given":"Joseph P.","family":"Erinjeri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jvir.2023.10.019_bib1","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1016\/j.jhep.2022.08.021","article-title":"Global burden of primary liver cancer in 2020 and predictions to 2040","volume":"77","author":"Rumgay","year":"2022","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jvir.2023.10.019_bib2","first-page":"1477","article-title":"Incidence and prognosis of liver metastasis at diagnosis: a pan-cancer population-based study","volume":"10","author":"Wang","year":"2020","journal-title":"Am J Cancer Res"},{"key":"10.1016\/j.jvir.2023.10.019_bib3","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/j.jhep.2021.11.018","article-title":"BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update","volume":"76","author":"Reig","year":"2022","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jvir.2023.10.019_bib4","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1038\/s41590-018-0044-z","article-title":"The immunology of hepatocellular carcinoma","volume":"19","author":"Ringelhan","year":"2018","journal-title":"Nat Immunol"},{"key":"10.1016\/j.jvir.2023.10.019_bib5","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1002\/hep.27793","article-title":"Liver inflammation abrogates immunological tolerance induced by Kupffer cells","volume":"62","author":"Heymann","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.jvir.2023.10.019_bib6","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1038\/nrclinonc.2011.30","article-title":"HCC and angiogenesis: possible targets and future directions","volume":"8","author":"Zhu","year":"2011","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.jvir.2023.10.019_bib7","doi-asserted-by":"crossref","first-page":"4876","DOI":"10.3390\/cancers13194876","article-title":"The role of cytokines in the different stages of hepatocellular carcinoma","volume":"13","author":"Rico Montanari","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.jvir.2023.10.019_bib8","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1038\/s41575-020-00395-0","article-title":"Locoregional therapies in the era of molecular and immune treatments for hepatocellular carcinoma","volume":"18","author":"Llovet","year":"2021","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.jvir.2023.10.019_bib9","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S1470-2045(08)70285-7","article-title":"Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial","volume":"10","author":"Cheng","year":"2009","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jvir.2023.10.019_bib10","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/S0140-6736(18)30207-1","article-title":"Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial","volume":"391","author":"Kudo","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.jvir.2023.10.019_bib11","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.783236","article-title":"Strategies to improve the antitumor effect of immunotherapy for hepatocellular carcinoma","volume":"12","author":"Xing","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.jvir.2023.10.019_bib12","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1053\/j.gastro.2018.09.051","article-title":"Targeted and immune-based therapies for hepatocellular carcinoma","volume":"156","author":"Greten","year":"2019","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jvir.2023.10.019_bib13","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1126\/science.aar4060","article-title":"Cancer immunotherapy using checkpoint blockade","volume":"359","author":"Ribas","year":"2018","journal-title":"Science"},{"key":"10.1016\/j.jvir.2023.10.019_bib14","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1111\/j.1600-065X.2008.00662.x","article-title":"Control of peripheral T-cell tolerance and autoimmunity via the CTLA-4 and PD-1 pathways","volume":"224","author":"Fife","year":"2008","journal-title":"Immunol Rev"},{"key":"10.1016\/j.jvir.2023.10.019_bib15","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.21037\/atm-20-4438","article-title":"Anti-PD1 monotherapy in hepatocellular carcinoma: a step forward or already behind?","volume":"8","author":"Catanese","year":"2020","journal-title":"Ann Transl Med"},{"key":"10.1016\/j.jvir.2023.10.019_bib16","doi-asserted-by":"crossref","first-page":"2991","DOI":"10.1200\/JCO.20.03555","article-title":"Safety, Efficacy, and pharmacodynamics of tremelimumab plus durvalumab for patients with unresectable hepatocellular carcinoma: randomized expansion of a phase I\/II study","volume":"39","author":"Kelley","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jvir.2023.10.019_bib17","article-title":"Advances in immune checkpoint inhibitors for advanced hepatocellular carcinoma","volume":"13","author":"Chen","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.jvir.2023.10.019_bib18","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma","volume":"382","author":"Finn","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jvir.2023.10.019_bib19","article-title":"Tremelimumab plus durvalumab in unresectable hepatocellular carcinoma","volume":"1","author":"Abou-Alfa","year":"2020","journal-title":"NEJM Evid"},{"key":"10.1016\/j.jvir.2023.10.019_bib20","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1038\/s41571-021-00573-2","article-title":"Immunotherapies for hepatocellular carcinoma","volume":"19","author":"Llovet","year":"2022","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.jvir.2023.10.019_bib21","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1148\/radiol.2019182326","article-title":"Immunotherapy and the interventional oncologist: challenges and opportunities-a Society of Interventional Oncology white paper","volume":"292","author":"Erinjeri","year":"2019","journal-title":"Radiology"},{"key":"10.1016\/j.jvir.2023.10.019_bib22","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1053\/j.gastro.2013.01.002","article-title":"Role of the microenvironment in the pathogenesis and treatment of hepatocellular carcinoma","volume":"144","author":"Hernandez-Gea","year":"2013","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jvir.2023.10.019_bib23","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/S0140-6736(00)04046-0","article-title":"Inflammation and cancer: back to Virchow?","volume":"357","author":"Balkwill","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.jvir.2023.10.019_bib24","doi-asserted-by":"crossref","first-page":"648","DOI":"10.2214\/AJR.16.17677","article-title":"Impact of interventional oncology therapies on tumor microenvironment and strategies to enhance their efficacy","volume":"210","author":"Fan","year":"2018","journal-title":"AJR Am J Roentgenol"},{"key":"10.1016\/j.jvir.2023.10.019_bib25","article-title":"Prognostic significance of inflammatory indices in hepatocellular carcinoma treated with transarterial chemoembolization: a systematic review and meta-analysis","volume":"15","author":"Li","year":"2020","journal-title":"PLoS One"},{"key":"10.1016\/j.jvir.2023.10.019_bib26","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1002\/1097-0142(19940101)73:1<53::AID-CNCR2820730111>3.0.CO;2-W","article-title":"Interleukin-6 in transcatheter arterial embolization for patients with hepatocellular carcinoma. Effects of serine protease inhibitor","volume":"73","author":"Matsuda","year":"1994","journal-title":"Cancer"},{"key":"10.1016\/j.jvir.2023.10.019_bib27","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1159\/000502774","article-title":"Hepatic artery embolization induces the local overexpression of transforming growth factor \u03b21 in a rat hepatoma model","volume":"9","author":"Ueshima","year":"2020","journal-title":"Liver Cancer"},{"key":"10.1016\/j.jvir.2023.10.019_bib28","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.4049\/jimmunol.178.3.1914","article-title":"Unmasking of alpha-fetoprotein-specific CD4(+) T cell responses in hepatocellular carcinoma patients undergoing embolization","volume":"178","author":"Ayaru","year":"2007","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.jvir.2023.10.019_bib29","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1016\/j.jvir.2016.01.150","article-title":"Peripheral blood regulatory T-cell and type 1 helper T-cell population decrease after hepatic artery embolization","volume":"27","author":"Takaki","year":"2016","journal-title":"J\u00a0Vasc Interv Radiol"},{"key":"10.1016\/j.jvir.2023.10.019_bib30","doi-asserted-by":"crossref","first-page":"2164","DOI":"10.1002\/ijc.24882","article-title":"Enhancement of tumor-specific T-cell responses by transcatheter arterial embolization with dendritic cell infusion for hepatocellular carcinoma","volume":"126","author":"Mizukoshi","year":"2010","journal-title":"Int J Cancer"},{"key":"10.1016\/j.jvir.2023.10.019_bib31","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1007\/s00270-019-02343-1","article-title":"Hepatic arterial bland embolization increases Th17 cell infiltration in a syngeneic rat model of hepatocellular carcinoma","volume":"43","author":"Avritscher","year":"2020","journal-title":"Cardiovasc Intervent Radiol"},{"key":"10.1016\/j.jvir.2023.10.019_bib32","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1007\/s12072-012-9409-9","article-title":"Cytokines are associated with postembolization fever and survival in hepatocellular carcinoma patients receiving transcatheter arterial chemoembolization","volume":"7","author":"Chao","year":"2013","journal-title":"Hepatol Int"},{"key":"10.1016\/j.jvir.2023.10.019_bib33","doi-asserted-by":"crossref","first-page":"3260","DOI":"10.1038\/s41598-019-40078-8","article-title":"Inflammatory cytokines and change of Th1\/Th2 balance as prognostic indicators for hepatocellular carcinoma in patients treated with transarterial chemoembolization","volume":"9","author":"Lee","year":"2019","journal-title":"Sci Rep"},{"key":"10.1016\/j.jvir.2023.10.019_bib34","doi-asserted-by":"crossref","first-page":"e1489","DOI":"10.1634\/theoncologist.2018-0669","article-title":"Postintervention interleukin-6 (IL-6) level, rather than the pretreatment or dynamic changes of IL-6, as an early practical marker of tumor response in hepatocellular carcinoma treated with transarterial chemoembolization","volume":"24","author":"Wu","year":"2019","journal-title":"Oncologist"},{"key":"10.1016\/j.jvir.2023.10.019_bib35","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.cyto.2015.07.001","article-title":"Interleukin-8 level as a prognostic marker in patients with hepatitis B virus-associated hepatocellular carcinoma treated with transarterial chemoembolization","volume":"76","author":"Kim","year":"2015","journal-title":"Cytokine"},{"key":"10.1016\/j.jvir.2023.10.019_bib36","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1016\/j.immuni.2007.07.023","article-title":"Interleukin-22 but not interleukin-17 provides protection to hepatocytes during acute liver inflammation","volume":"27","author":"Zenewicz","year":"2007","journal-title":"Immunity"},{"key":"10.1016\/j.jvir.2023.10.019_bib37","doi-asserted-by":"crossref","first-page":"28621","DOI":"10.18632\/oncotarget.16157","article-title":"Tumor SOCS3 methylation status predicts the treatment response to TACE and prognosis in HCC patients","volume":"8","author":"Jiang","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.jvir.2023.10.019_bib38","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1038\/nri.2017.49","article-title":"Chemokines in the cancer microenvironment and their relevance in cancer immunotherapy","volume":"17","author":"Nagarsheth","year":"2017","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.jvir.2023.10.019_bib39","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1186\/s12935-022-02771-z","article-title":"Targeted blocking of CCR2 and CXCR2 improves the efficacy of transarterial chemoembolization of hepatocarcinoma","volume":"22","author":"Tian","year":"2022","journal-title":"Cancer Cell Int"},{"key":"10.1016\/j.jvir.2023.10.019_bib40","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1016\/j.jvir.2023.01.032","article-title":"Correlation of serum chemokine ligand 14 with Barcelona Clinic Liver Cancer stage, lymphocyte profile, and response to transarterial chemoembolization in patients with hepatocellular carcinoma","volume":"34","author":"Guo","year":"2023","journal-title":"J\u00a0Vasc Interv Radiol"},{"key":"10.1016\/j.jvir.2023.10.019_bib41","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1007\/s11596-007-0117-y","article-title":"Relationship between the changes of VEGF level and dendritic cells in peripheral blood of patients with hepatocellular carcinoma after transcatheter arterial chemoembolization","volume":"27","author":"Liu","year":"2007","journal-title":"J\u00a0Huazhong Univ Sci Technolog Med Sci"},{"key":"10.1016\/j.jvir.2023.10.019_bib42","article-title":"Trans-arterial chemoembolization as a loco-regional inducer of immunogenic cell death in hepatocellular carcinoma: implications for immunotherapy","volume":"9","author":"Pinato","year":"2021","journal-title":"J\u00a0Immunother Cancer"},{"key":"10.1016\/j.jvir.2023.10.019_bib43","doi-asserted-by":"crossref","first-page":"6065","DOI":"10.3892\/mmr.2015.4171","article-title":"Effect of transcatheter arterial chemoembolization on cellular immune function and regulatory T cells in patients with hepatocellular carcinoma","volume":"12","author":"Liao","year":"2015","journal-title":"Mol Med Rep"},{"key":"10.1016\/j.jvir.2023.10.019_bib44","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1007\/s11596-008-0606-7","article-title":"Changes of CD4(+) CD25 (+) regulatory T cells in peripheral blood in patients with hepatocellular carcinoma before and after TACE","volume":"28","author":"Xiong","year":"2008","journal-title":"J\u00a0Huazhong Univ Sci Technolog Med Sci"},{"key":"10.1016\/j.jvir.2023.10.019_bib45","doi-asserted-by":"crossref","first-page":"554","DOI":"10.3892\/ol.2021.12815","article-title":"Effects of transarterial chemoembolization on the immunological function of patients with hepatocellular carcinoma","volume":"22","author":"Guo","year":"2021","journal-title":"Oncol Lett"},{"key":"10.1016\/j.jvir.2023.10.019_bib46","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1111\/his.14317","article-title":"Transarterial chemoembolisation enhances programmed death-1 and programmed death-ligand 1 expression in hepatocellular carcinoma","volume":"79","author":"Montasser","year":"2021","journal-title":"Histopathology"},{"key":"10.1016\/j.jvir.2023.10.019_bib47","article-title":"Increased circulating Th17 cells after transarterial chemoembolization correlate with improved survival in stage III hepatocellular carcinoma: a prospective study","volume":"8","author":"Liao","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.jvir.2023.10.019_bib48","doi-asserted-by":"crossref","first-page":"212","DOI":"10.3390\/cancers12010212","article-title":"Association of TIM-3 with BCLC stage, serum PD-L1 detection, and response to transarterial chemoembolization in patients with hepatocellular carcinoma","volume":"12","author":"Tampaki","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.jvir.2023.10.019_bib49","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1111\/liv.12592","article-title":"Radioembolization of hepatocellular carcinoma activates liver regeneration, induces inflammation and endothelial stress and activates coagulation","volume":"35","author":"Fernandez-Ros","year":"2015","journal-title":"Liver Int"},{"key":"10.1016\/j.jvir.2023.10.019_bib50","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1111\/hpb.12095","article-title":"Partial liver volume radioembolization induces hypertrophy in the spared hemiliver and no major signs of portal hypertension","volume":"16","author":"Fern\u00e1ndez-Ros","year":"2014","journal-title":"HPB (Oxford)"},{"key":"10.1016\/j.jvir.2023.10.019_bib51","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1007\/s00270-017-1622-4","article-title":"Cytokines and 90Y-radioembolization: relation to liver function and overall survival","volume":"40","author":"Seidensticker","year":"2017","journal-title":"Cardiovasc Intervent Radiol"},{"key":"10.1016\/j.jvir.2023.10.019_bib52","doi-asserted-by":"crossref","first-page":"2349","DOI":"10.1002\/ijc.27894","article-title":"Immunogenic cell death biomarkers HMGB1, RAGE, and DNAse indicate response to radioembolization therapy and prognosis in colorectal cancer patients","volume":"132","author":"Fahmueller","year":"2013","journal-title":"Int J Cancer"},{"key":"10.1016\/j.jvir.2023.10.019_bib53","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1007\/s12325-016-0324-7","article-title":"Transarterial radioembolization with yttrium-90 for the treatment of hepatocellular carcinoma","volume":"33","author":"Kallini","year":"2016","journal-title":"Adv Ther"},{"key":"10.1016\/j.jvir.2023.10.019_bib54","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1136\/gutjnl-2017-315485","article-title":"Immune activation underlies a sustained clinical response to yttrium-90 radioembolisation in hepatocellular carcinoma","volume":"68","author":"Chew","year":"2019","journal-title":"Gut"},{"key":"10.1016\/j.jvir.2023.10.019_bib55","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1148\/radiol.220158","article-title":"Prospective evaluation of immune activation associated with response to radioembolization assessed with PET\/CT in women with breast cancer liver metastasis","volume":"306","author":"Deipolyi","year":"2023","journal-title":"Radiology"},{"key":"10.1016\/j.jvir.2023.10.019_bib56","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.trsl.2012.01.011","article-title":"An inflammation-based prognostic index predicts survival advantage after transarterial chemoembolization in hepatocellular carcinoma","volume":"160","author":"Pinato","year":"2012","journal-title":"Transl Res"},{"key":"10.1016\/j.jvir.2023.10.019_bib57","doi-asserted-by":"crossref","first-page":"509","DOI":"10.3390\/cancers11040509","article-title":"Development of a new nomogram including neutrophil-to-lymphocyte ratio to predict survival in patients with hepatocellular carcinoma undergoing transarterial chemoembolization","volume":"11","author":"Chon","year":"2019","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.jvir.2023.10.019_bib58","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1016\/j.jvir.2010.12.041","article-title":"Blood neutrophil-to-lymphocyte ratio predicts survival in patients with unresectable hepatocellular carcinoma undergoing transarterial chemoembolization","volume":"22","author":"Huang","year":"2011","journal-title":"J\u00a0Vasc Interv Radiol"},{"key":"10.1016\/j.jvir.2023.10.019_bib59","article-title":"Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios as predictors of survival and metastasis for recurrent hepatocellular carcinoma after transarterial chemoembolization","volume":"10","author":"Fan","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.jvir.2023.10.019_bib60","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.2147\/CMAR.S190545","article-title":"The prognostic and predictive value of the combination of the neutrophil-to-lymphocyte ratio and the platelet-to-lymphocyte ratio in patients with hepatocellular carcinoma who receive transarterial chemoembolization therapy","volume":"11","author":"He","year":"2019","journal-title":"Cancer Manag Res"},{"key":"10.1016\/j.jvir.2023.10.019_bib61","doi-asserted-by":"crossref","first-page":"5358","DOI":"10.18632\/aging.202468","article-title":"The lymphocyte-C-reactive protein ratio as the optimal inflammation-based score in patients with hepatocellular carcinoma underwent TACE","volume":"13","author":"Lu","year":"2021","journal-title":"Aging (Albany NY)"},{"key":"10.1016\/j.jvir.2023.10.019_bib62","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1148\/radiol.2017170731","article-title":"Assessment of response to transcatheter arterial chemoembolization with doxorubicin-eluting microspheres: tumor biology and hepatocellular carcinoma recurrence in a 5-year transplant cohort","volume":"286","author":"Sandow","year":"2018","journal-title":"Radiology"},{"key":"10.1016\/j.jvir.2023.10.019_bib63","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1245\/s10434-014-4050-6","article-title":"Neutrophil-lymphocyte ratio is a simple and novel biomarker for prediction of survival after radioembolization for metastatic colorectal cancer","volume":"22","author":"Tohme","year":"2015","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.jvir.2023.10.019_bib64","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1016\/j.jvir.2018.02.020","article-title":"Predictors of survival after yttrium-90 radioembolization for colorectal cancer liver metastases","volume":"29","author":"Weiner","year":"2018","journal-title":"J\u00a0Vasc Interv Radiol"},{"key":"10.1016\/j.jvir.2023.10.019_bib65","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1016\/j.jvir.2015.01.038","article-title":"The prognostic role of neutrophil-to-lymphocyte ratio in patients with unresectable hepatocellular carcinoma treated with radioembolization","volume":"26","author":"Sukato","year":"2015","journal-title":"J\u00a0Vasc Interv Radiol"},{"key":"10.1016\/j.jvir.2023.10.019_bib66","doi-asserted-by":"crossref","first-page":"2624","DOI":"10.1007\/s00259-020-05186-y","article-title":"Prognostic significance of neutrophil to lymphocyte ratio dynamics in patients with hepatocellular carcinoma treated with radioembolization using glass microspheres","volume":"48","author":"Li","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.jvir.2023.10.019_bib67","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/s00270-022-03313-w","article-title":"Evaluation of inflammatory scores in metastatic colorectal cancer patients undergoing transarterial radioembolization","volume":"46","author":"Young","year":"2023","journal-title":"Cardiovasc Intervent Radiol"}],"container-title":["Journal of Vascular and Interventional Radiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S105104432300787X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S105104432300787X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T06:10:50Z","timestamp":1760940650000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S105104432300787X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2]]},"references-count":67,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,2]]}},"alternative-id":["S105104432300787X"],"URL":"https:\/\/doi.org\/10.1016\/j.jvir.2023.10.019","relation":{},"ISSN":["1051-0443"],"issn-type":[{"value":"1051-0443","type":"print"}],"subject":[],"published":{"date-parts":[[2024,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immune Effects of Intra-Arterial Liver-Directed Therapies","name":"articletitle","label":"Article Title"},{"value":"Journal of Vascular and Interventional Radiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jvir.2023.10.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 SIR, 2023","name":"copyright","label":"Copyright"}]}}